BIOTECH & BIOPHARMA discussed on CNBC-discussing consistent long term growth prospects of industry, discussing big drug co.'s
- one is marketing drugs, & another growth area is one that discovers drugs & innovates
- now, it's a GUD thing to have both at Knight.
GUD + GBT + $250 MILLION+, of future acquisitions or drug purchases